News

Filter

1 to 9 of 230 results

Oncolytics Biotech gains third orphan status for Reolysin

Oncolytics Biotech gains third orphan status for Reolysin

03-03-2015

Canada’s Oncolytics Biotech revealed today that the US Food and Drug Administration has granted Orphan…

BiotechnologyOncologyOncolytics BiotechRare diseasesRegulationReolysinUSA

Shire acquires Meritage Pharma, strengthening rare diseases pipeline

Shire acquires Meritage Pharma, strengthening rare diseases pipeline

24-02-2015

In a second acquisition this year, Ireland-headquartered Shire revealed today that it has taken control…

BiotechnologyGastro-intestinalsMergers & AcquisitionsMeritage PharmaRare diseasesShire

Sosei acquires Heptares Therapeutics for up to $400 million

Sosei acquires Heptares Therapeutics for up to $400 million

23-02-2015

Japanese drugmaker Sosei Group says it has acquired Heptares Therapeutics, a clinical-stage private UK-based…

BiotechnologyHeptares TherapeuticsMergers & AcquisitionsNeurologicalRare diseasesSosei

EMA Orphan Drug status for aTyr’s Resolaris in FSHD

18-02-2015

Privately-held US biotech firm aTyr Pharma says that the European Commission has granted Orphan Drug…

ATyr PharmaBiotechnologyEuropeRare diseasesRegulationResolaris

Australia to subsidize Genzyme’s Pompe disease drug Myozyme for young patients

Australia to subsidize Genzyme’s Pompe disease drug Myozyme for young patients

17-02-2015

Australia’s Minister for Health Sussan Ley said today that she has approved a life-saving drug that…

AustraliaBiotechnologyFinancialGenzymeHealthcareMyozymeRare diseasesSanofi

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

13-02-2015

French pharma major Sanofi subsidiary Genzyme has reported positive extension study data from its Phase…

BiotechnologyCerdelgaGenzymeRare diseasesResearchSanofi

Strong 2014 financials from Shire, bolstered by

Strong 2014 financials from Shire, bolstered by "break fee"

12-02-2015

Shares of Ireland-headquartered Shire gained 4.6% to £49.97, after the drugmaker reported pretax profit…

BiotechnologyFinancialRare diseasesShire

Alexion’s Soliris price to be reviewed by Canadian regulator

07-02-2015

Canada’s Patented Medicine Prices review Board (PMPRB) will hold a public hearing in the matter of…

Alexion PharmaceuticalsBiotechnologyCanadaPricingRare diseasesSoliris

1 to 9 of 230 results

COMPANY SPOTLIGHT

Menarini

Back to top